Table 2. Laboratory Data of the Studied AML Cases at Presentation.
| Parameters | Number of cases (N = 50) |
|
|---|---|---|
| N | % | |
| WHO classification of AML cases | ||
| AML with recurrent cytogenetics | ||
| AML with t(8;21) | 4 | 8.0 |
| AML with inv16 | 3 | 6.0 |
| Acute promyelocytic leukemia with PML/RARA | 7 | 14.0 |
| AML with t(6;9) | 1 | 2.0 |
| AML with bi-allelic mutation of CEPBA | 1 | 2.0 |
| AML without maturation | 7 | 14.0 |
| AML with maturation | 12 | 24.0 |
| Acute myelomonocytic leukemia | 10 | 20.0 |
| Acute monoblastic/monocytic leukemia | 3 | 6.0 |
| Pure erythroid leukemia | 2 | 4.0 |
| Conventional karyotyping | ||
| Normal | 43 | 86.0 |
| 47,xy,+8 | 4 | 8.0 |
| 47,xy,+9 | 1 | 2.0 |
| 46,xy,-9 | 1 | 2.0 |
| 46,xy,t(6:9) | 1 | 2.0 |
| Cancer cytogenetics (FISH) | 34 | |
| Positive | ||
| inv16 | 3 | 6.0 |
| t(15;17) | 7 | 14.0 |
| t(8;21) | 4 | 8.0 |
| Negative | 20 | 40 |
| Not available | 16 | 32 |
AML: acute myeloid leukemia; FISH: fluorescent in situ hybridization.